Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong

Pak-Leung Ho, Tak-Lun Que, Dominic Ngai-Chong Tsang, Tak-Keung Ng, Kin-Hung Chow, Wing-Hon Seto
Pak-Leung Ho
Department of Microbiology, Division of Infectious Diseases, University of Hong Kong,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tak-Lun Que
Department of Pathology, Tuen Mun Hospital,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominic Ngai-Chong Tsang
Department of Microbiology, Queen Elizabeth Hospital, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tak-Keung Ng
Department of Microbiology, Princess Margaret Hospital, Hong Kong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kin-Hung Chow
Department of Microbiology, Division of Infectious Diseases, University of Hong Kong,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wing-Hon Seto
Department of Microbiology, Queen Mary Hospital,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.5.1310
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The MICs of 17 antimicrobial agents for 181 Streptococcus pneumoniae strains were determined by the E-test. Overall, 69.1% were penicillin resistant (MIC > 0.06 μg/ml). Resistance to ciprofloxacin (MIC > 2 μg/ml), levofloxacin (MIC > 2 μg/ml), or trovafloxacin (MIC > 1 μg/ml) was found in 12.1, 5.5, or 2.2% of the strains, respectively. These high rates of resistance raise concerns for the future.

The resistance ofStreptococcus pneumoniae to β-lactams, macrolides, tetracyclines, and chloramphenicol has been increasing rapidly in southeast Asia (1). Some of the newer fluoroquinolones, by virtue of their excellent in vitro activity against S. pneumoniae, oral bioavailability, and tissue penetration, hold promise as the drugs of choice for therapy of respiratory tract infections due to multiple drug-resistant S. pneumoniae in this region (6). We have therefore conducted a study on the in vitro activities of 3 fluoroquinolones and 13 other antimicrobial agents.

A total of 181 consecutive, nonduplicate isolates of S. pneumoniae were obtained from four regional laboratories (61 isolates from laboratory A, 41 isolates from laboratory B, 31 isolates from laboratory C, and 49 isolates from laboratory D) during the second half of 1998. These four laboratories provide microbiology service to seven public hospitals, serving a population of about 3 million in the Hong Kong island (south and west), Kowloon (central), and the New Territory (south and north) regions of Hong Kong. The strains were isolated from throat (5), nose (4), eye (5), sputum (143), tracheal aspirate (4), and blood (21). Strains were identified asS. pneumoniae by Gram stain, colony morphology, optochin susceptibility, and bile solubility.

The MICs of ciprofloxacin, levofloxacin, trovafloxacin, penicillin, ampicillin, ticarcillin-clavulanate, piperacillin-tazobactam, cefuroxime, cefpodoxime, ceftibuten, ceftriaxone, cefepime, meropenem, erythromycin, azithromycin, clindamycin, and vancomycin were determined by the E-test (AB Biodisk, Solna, Sweden) following the manufacturer’s instructions. All susceptibility testings were done in the University of Hong Kong by one technician. Susceptibility tests were performed from a bacterial inoculum whose turbidity was equivalent to that of a McFarland standard of 0.5. From this suspension, E-tests were performed on Mueller-Hinton agar with 5% sheep blood (Micro Diagnostics Incorporated, Lombard, Ill.). The plates were incubated at 35°C in 5% CO2 for 20 to 24 h (10). MICs falling between two marks on the E-test strip were rounded up to the next higher twofold dilution, as recommended in the instructions. Quality control strains (S. pneumoniae ATCC 49619,Staphylococcus aureus ATCC 29213, and Escherichia coli ATCC 25922) were included with each run. Interpretation of results was performed according to recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (8). Because the NCCLS breakpoints for microbroth dilution appear to have limited applicability to E-test results for macrolides versus S. pneumoniae, modified breakpoints as recommended by the manufacturer were used (2). For erythromycin, the breakpoints were as follows: susceptible, ≤0.5 μg/ml; intermediate, 1 μg/ml; and resistant, ≥2 μg/ml. For azithromycin, the following breakpoints were used: susceptible, ≤4 μg/ml; intermediate, 8 μg/ml; and resistant, ≥16 μg/ml. No reference breakpoints for cefpodoxime, ceftibuten, ticarcillin-clavulanate, piperacillin-tazobactam, and ciprofloxacin are available. Multiple drug resistance is defined as resistance to at least one member from each of the three classes of antimicrobial agents including the β-lactams, macrolides, and fluoroquinolones. The chi-square, Fisher exact, or Kruskal-Wallis test was used for statistical analysis.

The susceptibilities of the 181 pneumococcal isolates to 17 antimicrobial agents are summarized in Table1. Rates of resistance to penicillin (MIC > 0.06 μg/ml) were 60.7% (37 of 61) for laboratory A, 80.5% (33 of 41) for laboratory B, 54.8% (17 of 31) for laboratory C, and 79.2% (38 of 48) for laboratory D (P = 0.05 for median MICs, Kruskal-Wallis test). Penicillin resistance rates were similar for children (age, ≤12 years) and adults (age, >12 years) (73.8 versus 66.4%, respectively; P > 0.05) but penicillin resistance was less common for blood isolates than for isolates from other sites (33.3 versus 73.8%, respectively; P < 0.01). Thirty-four (18.8%) isolates were highly resistant to penicillin with MICs of >2 μg/ml. For the most resistant isolate, the MIC was 6 μg/ml. The MICs of ampicillin and piperacillin-tazobactam for most strains were within one dilution difference of that of penicillin. However, the MIC of ticarcillin-clavulanate increased disproportionately with an increasing level of resistance to penicillin (data not shown). Ceftriaxone had the lowest MIC50 (MIC at which 50% of isolates were inhibited) and MIC90 among the cephalosporins, followed by cefepime, cefpodoxime, and cefuroxime. Multiple drug resistance was found in 12.1% (22 of 181) of the isolates.

View this table:
  • View inline
  • View popup
Table 1.

Susceptibilities of 181 isolates of S. pneumoniae stratified by penicillin susceptibility

The distribution of MICs for the fluoroquinolones are shown in Fig.1. Ciprofloxacin was the least active fluoroquinolone with a MIC of >2 μg/ml for 12.1% (22 of 181) of the isolates. Importantly, resistance to levofloxacin and trovafloxacin was only found in the penicillin-resistant isolates. Trovafloxacin was highly active, with similar MIC90s for both penicillin-susceptible and -resistant isolates. However, all four trovafloxacin-resistant isolates were also penicillin and macrolide resistant (Table 2).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Distribution of MICs of three fluoroquinolones for 181 strains of S. pneumoniae.

View this table:
  • View inline
  • View popup
Table 2.

Distribution and MICs of four β-lactam–macrolide–fluoroquinolone-resistant pneumococci

A marked increase in the overall prevalence of resistance to penicillin (69.1%) was found compared to rates from previous studies in 1993 (18%) and 1995 (28.9%) in Hong Kong (5, 7). While resistance to penicillin among S. pneumoniae isolates is an emerging problem worldwide, this high rate of resistance (>60%) has only been reported in several Asian countries, including Korea (73.4%), Taiwan (71%), Japan (67.7%), and Thailand (63.1%) (1, 12). High rates of cross-resistance to the cephalosporins (64 to 88%) and meropenem (80.2%) among the penicillin-intermediate or -resistant isolates were also found.

The overall rate of resistance to erythromycin also rose dramatically from 10% in 1993 and 39.2% in 1995 to 78.5% in the present study (3). The overall consumption of antimicrobial agents is frequently identified as a risk factor for the rapid emergence of resistance. Notably, the consumption of macrolides in Hong Kong increased by more than twofold from 1994 to 1997 (13). In addition, overcrowdedness may be another factor that contributes to the rapid dissemination of drug-resistant S. pneumoniae in Hong Kong. This is supported by findings from Ip and coworkers (6) that 70% of the penicillin-resistant strains belong to a variant of the Spanish type 23F clone.

The emergence of fluoroquinolone-resistant S. pneumoniae is alarming because this group of antimicrobial agents is at present the only possible option for oral therapy of infection due to β-lactam–macrolide-resistant strains. Within 3 years, the rate of resistance to fluoroquinolones has increased from <0.5% for ofloxacin (5) to 5.5% for levofloxacin (MIC > 2 μg/ml). This is in contrast to the lack of development of resistance reported in other areas (2, 11, 14). Most alarming, 4% of the penicillin-resistant isolates were already highly resistant to trovafloxacin, an agent only registered for use in Hong Kong in October 1998.

In conclusion, we have reported extremely high rates of resistance to β-lactams and macrolides among S. pneumoniae isolates in Hong Kong. Trovafloxacin is highly active in vitro against β-lactam–macrolide-resistant strains. However, ominous resistance to fluoroquinolones is emerging. The global mobility of human populations and the convergence of tourist and business traffic in Hong Kong will likely facilitate the worldwide spread of these very resistant clones (7).

ACKNOWLEDGMENTS

This study was supported by grants from the Committee on Research and Conference Grant, The University of Hong Kong, and the Pfizer Corporation, Hong Kong.

We thank Allan Ronald for a critical reading of the manuscript.

FOOTNOTES

    • Received 8 December 1998.
    • Returned for modification 29 January 1999.
    • Accepted 3 March 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Chiou C. C.,
    2. Liu Y. C.,
    3. Huang T. S.,
    4. Hwang W. K.,
    5. Wang J. H.,
    6. Lin H. H.,
    7. Yen M. Y.,
    8. Hsieh K. S.
    Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J. Clin. Microbiol. 36 1998 1933 1937
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cunha B. A.,
    2. Qadri S. M.,
    3. Ueno Y.,
    4. Walters E. A.,
    5. Domenico P.
    Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J. Antimicrob. Chemother. 39 (Suppl. B) 1997 29 34
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Fasola E. L.,
    2. Bajaksouzian S.,
    3. Appelbaum P. C.,
    4. Jacobs M. R.
    Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob. Agents Chemother. 41 1997 129 134
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gerardo S. H.,
    2. Citron D. M.,
    3. Claros M. C.,
    4. Goldstein E. J. C.
    Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob. Agents Chemother. 40 1996 2413 2415
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ho P. L.,
    2. Yuen K. Y.,
    3. Yam W. C.,
    4. Wong S. S. Y.,
    5. Luk W. K.
    Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J. Hosp. Infect. 31 1995 305 317
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ip M.,
    2. Lyon D. J.,
    3. Yung R. W. H.,
    4. Chan C.,
    5. Cheng A. F.
    Molecular epidemiology of penicillin- and multidrug-resistant Streptococcus pneumoniae in Hong Kong, abstr. C20 Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 74 American Society for Microbiology Washington, D.C
  7. 7.↵
    1. Kam K. M.,
    2. Luey K. Y.,
    3. Fung S. M.,
    4. Yiu P. P.,
    5. Harden T. J.,
    6. Cheung M. M.
    Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 39 1995 2667 2670
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Klugman K. P.,
    2. Gootz T. D.
    In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 39 (Suppl. B) 1997 51 55
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    1. Munoz R.,
    2. Coffey T. J.,
    3. Daniels M.,
    4. Dowson C. G.,
    5. Laible G.,
    6. Casal J.,
    7. et al.
    Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J. Infect. Dis. 164 1991 302 306
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing, 8th informational supplement. M100-S8. 1998 National Committee for Clinical Laboratory Standards Villanova, Pa
  11. 11.↵
    1. Plouffe J. F.
    Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group. Diagn. Microbiol. Infect. Dis. 25 1996 43 45
    OpenUrl
  12. 12.↵
    1. Song J. H.,
    2. the Asian Network for Surveillance of Resistant Pneumococci (ANSORP) Study Group
    Prevalence of drug-resistant pneumococci in 11 Asian countries, abstr. C48 Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 54 American Society for Microbiology Washington, D.C
  13. 13.↵
    1. Tam C. Y.
    Extremely high rate of resistance to the macrolides in Hong Kong. Ming Pao Post 1998 Nov. 25 1998 A2
    OpenUrl
  14. 14.↵
    1. Thornsberry C.,
    2. Ogilvie P.,
    3. Kahn J.,
    4. Mauriz Y.
    Surveillance of antimicrobial resistance in Streptococcus pneumoniae,Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. The Laboratory Investigator Group. Diagn. Microbiol. Infect. Dis. 29 1997 249 257
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong
Pak-Leung Ho, Tak-Lun Que, Dominic Ngai-Chong Tsang, Tak-Keung Ng, Kin-Hung Chow, Wing-Hon Seto
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1310-1313; DOI: 10.1128/AAC.43.5.1310

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong
Pak-Leung Ho, Tak-Lun Que, Dominic Ngai-Chong Tsang, Tak-Keung Ng, Kin-Hung Chow, Wing-Hon Seto
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1310-1313; DOI: 10.1128/AAC.43.5.1310
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
Drug Resistance, Multiple
Pneumococcal Infections
Streptococcus pneumoniae

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596